CAMBRIDGE, Mass.--(BUSINESS WIRE)--SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced the appointment of James M. Frates to the company’s board of directors.
“Jim’s experience building a fully integrated, CNS-focused biopharmaceutical company, coupled with his strong financial background, will add a valuable perspective to our board of directors,” said Jeff Jonas, M.D., chief executive officer of SAGE Therapeutics. “I am pleased to welcome Jim to the SAGE team and look forward to benefiting from his insights as we strategically expand our infrastructure and advance our clinical and preclinical programs.”
Mr. Frates currently serves as senior vice president and chief financial officer at Alkermes, where he manages all aspects of finance and helped oversee the 2011 business combination with Elan Drug Technologies (EDT). Prior to joining Alkermes, Mr. Frates served as vice president of the East Coast Life Sciences Practice at Robertson, Stephens & Company and before that, served as a financial analyst in the Healthcare Group at Morgan Stanley & Company, Inc. Mr. Frates serves as a trustee of St. Paul’s School and has served on the board of directors of GPC Biotech and the Association of Bioscience Financial Officers, and as a member of the NASDAQ Issuer Affairs Committee on Sarbanes-Oxley Reform. Mr. Frates holds a B.A. in government from Harvard University and an MBA from Harvard University Graduate School of Business Administration.
“I am pleased to be joining the SAGE Therapeutics board as the company makes important clinical advances, including progress in its Phase 1/2 clinical trial for SAGE-547 in super-refractory status epilepticus,” said Mr. Frates. “I look forward to collaborating with the SAGE team in its efforts to discover and develop new treatments for patients in this disease area where there remains significant unmet medical need.”
About SAGE Therapeutics
SAGE Therapeutics is a biopharmaceutical company committed to developing and commercializing novel medicines to treat life-threatening, rare CNS disorders. SAGE’s lead program, SAGE-547, is in clinical development for super-refractory status epilepticus and is the first of several compounds the company is developing in its portfolio of potential seizure medicines. SAGE’s proprietary chemistry platform has generated multiple new compounds that target GABAA and NMDA receptors, which are broadly accepted as impacting many psychiatric and neurological disorders. SAGE Therapeutics is a private company launched in 2010 by an experienced team of R&D leaders, CNS experts and investors. For more information, please visit www.sagerx.com.